Septerna盘前大涨70%!诺和诺德口服小分子减肥药牵手成功

Jo的随笔
14 May

在口服减肥药领域,一场巨头间的激烈角逐正悄然展开。Septerna盘前大涨70%!诺和诺德最终在小分子口服减肥药赛道,选择了Septerna。诺和诺德自去年 12 月公布 CagriSema(胰淀素类似物 cagrilintide 和 GLP-1 受体激动剂司美格鲁肽的组合)3 期结果后,股价遭遇重挫。原因在于 68 周后患者减重 22.7%,未达公司预期的 25%。为扭转局面,诺和诺德全面开启...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10